Giovanni Targher

Prof. Dr. Giovanni Targher

University of Verona, Department of Medicine, Section of Diabetes and Endocrinology
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
MEMohammed Eslam
Mohammed Eslam
PNPhilip Noel Newsome
Philip Noel Newsome
SSShiv K. Sarin
Shiv K. Sarin
QAQuentin M. Anstee
Quentin M. Anstee
Giovanni TargherGiovanni Targher
Giovanni Targher
JGJacob George
Jacob George

30 September 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
Giovanni TargherGiovanni Targher
Giovanni Targher
CDChristopher P. Day
Christopher P. Day
EBEnzo Bonora
Enzo Bonora
Growing evidence suggests that nonalcoholic fatty liver disease is associated with an increased risk of cardiovascular disease beyond that conferred by established risk factors.

1 September 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
Giovanni TargherGiovanni Targher
Giovanni Targher
CBChris Byrne
Chris Byrne
Amedeo LonardoAmedeo Lonardo
Amedeo Lonardo
GZGiacomo Zoppini
Giacomo Zoppini
CBCorrado Barbui
Corrado Barbui

17 March 2017 in Gut
Verified
Journal Article
Open access
PDF file
LALeon A Adams
Leon A Adams
QAQuentin M. Anstee
Quentin M. Anstee
HTHerbert Tilg
Herbert Tilg
Giovanni TargherGiovanni Targher
Giovanni Targher
Key physiological functions of the liver, including glucose and lipid metabolism, become disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated with a systemic inflammatory ‘ milieu ’ initiated in part by liver-secreted cytokines and molecules. Consequently, the pathophysiological effects of NAFLD extend beyond the liver with a large body of clinical evidence demonstrating NAFLD to be independently associated with both prevalent and incident cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). The magnitude of risk of developing these extrahepatic diseases parallels the underlying severity of NAFLD, such that patients with non-alcoholic steatohepatitis (NASH) appear to be at greater risk of incident CVD, CKD and T2DM than those with simple steatosis. Other modifiers of risk may include genetic variants (eg, patatin-like phospholipase domain-containing 3 and trans-membrane 6 superfamily member 2 polymorphisms), visceral adipose tissue accumulation, dietary intake and the gut microbiome. Emerging data also suggest that NAFLD may be a risk factor for colonic neoplasia and reduced bone mineral density, especially among men. Importantly, improvement/resolution of NAFLD is associated with a reduced incidence of T2DM and improved kidney function, adding weight to causality and suggesting liver focused treatments may reduce risk of extrahepatic complications. Awareness of these associations is important for the clinicians such that CVD risk factor management, screening for T2DM and CKD are part of the routine management of patients with NAFLD.

16 January 2024 in Gut
Verified
Journal Article
Closed access
PDF file
Giovanni TargherGiovanni Targher
Giovanni Targher
CBChris Byrne
Chris Byrne
HTHerbert Tilg
Herbert Tilg
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a multisystem disease where systemic insulin resistance and related metabolic dysfunction play a pathogenic role in the development of NAFLD and its most relevant liver-related morbidities (cirrhosis, liver failure and hepatocellular carcinoma) and extrahepatic complications, such as cardiovascular disease (CVD), type 2 diabetes mellitus, chronic kidney disease, and certain types of extrahepatic cancers. In 2023, three large multinational liver associations proposed that metabolic dysfunction-associated steatotic liver disease (MASLD) should replace the term NAFLD; the name chosen to replace non-alcoholic steatohepatitis was metabolic dysfunction-associated steatohepatitis (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between NAFLD and MASLD definitions—that is, ~99% of individuals with NAFLD meet MASLD criteria. In this narrative review, we provide an overview of the literature on (a) the recent epidemiological data on MASLD and the risk of developing CVD and malignant complications, (b) the underlying mechanisms by which MASLD (and factors strongly linked with MASLD) may increase the risk of these extrahepatic complications and (c) the diagnosis and assessment of CVD risk and potential treatments to reduce CVD risk in people with MASLD or MASH.

10 May 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
Giovanni TargherGiovanni Targher
Giovanni Targher
KCKathleen E. Corey
Kathleen E. Corey
CBChris Byrne
Chris Byrne
MRMichael Roden
Michael Roden